Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0129275Aexternal-prioritypatent/GB0129275D0/en
Application filed by PfizerfiledCriticalPfizer
Publication of UY27308A1publicationCriticalpatent/UY27308A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente invención se refiere a una combinación de un agonista del recptor A2a de adenosina y un agente anticolinérgico para la administración simultánea, consecutiva o separada por vía de inhalación en el tratamiento de una enfermedad obstructiva de las vías aéreas u otra enfermedad inflamatoria, con la condición de que el agente anticolinérgico no sea una sal de tiotropio.The present invention relates to a combination of an adenosine A2a receptor receptor agonist and an anticholinergic agent for simultaneous, consecutive or separate administration by inhalation in the treatment of an obstructive airway disease or other inflammatory disease, with the condition that the anticholinergic agent is not a tiotropium salt.
UY27308A2001-05-252002-05-24
AN A2A AGONIST IN COMBINATION WITH AN ANTI-POLYNERGIC AGENT FOR THE TREATMENT OF OBSTRUCTIVE DISEASES OF THE AIRWAYS
UY27308A1
(en)
Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases.
Restless Leg Syndrome Treatment Method, Adenoin a2a Receptor Antagonist Use, Therapeutic Agent for Restless Leg Syndrome, and Night Myoclonus Treatment Method